MediciNova (NASDAQ:MNOV) versus Fortress Biotech (NASDAQ:FBIO) Financial Review

Fortress Biotech (NASDAQ:FBIO) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Volatility and Risk

Fortress Biotech has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Valuation & Earnings

This table compares Fortress Biotech and MediciNova”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$68.47 million	0.97	$6.82 million	$2.64	0.75
MediciNova	$410,000.00	168.07	-$12.00 million	($0.21)	-6.67

Fortress Biotech has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Comparatively, 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Fortress Biotech and MediciNova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
MediciNova	-1,168.70%	-26.51%	-24.39%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Fortress Biotech and MediciNova, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1	1	2	0	2.25
MediciNova	1	1	4	1	2.71

Fortress Biotech currently has a consensus price target of $17.00, indicating a potential upside of 754.27%. MediciNova has a consensus price target of $7.75, indicating a potential upside of 453.57%. Given Fortress Biotech’s higher possible upside, analysts clearly believe Fortress Biotech is more favorable than MediciNova.

Summary

Fortress Biotech beats MediciNova on 10 of the 14 factors compared between the two stocks.

About Fortress Biotech

Fortress Biotech, Inc. (NASDAQ: FBIO) is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiary companies and strategic partnerships. Its research and development activities have focused on areas including dermatology, immunology, oncology, rare diseases and other conditions with significant unmet medical needs. The company’s portfolio has included dermatology products such as ZILXI, a topical minocycline foam for the treatment of inflammatory lesions associated with rosacea, and Qbrexza, a topical treatment for primary axillary hyperhidrosis.

About MediciNova

MediciNova, Inc. (NASDAQ: MNOV) is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops small-molecule therapies for diseases with significant unmet medical needs, with a primary focus on neurological, neurodegenerative, and other serious medical conditions. Its lead development program is MN-166, also known as ibudilast, an orally administered compound with anti-inflammatory and neuroprotective properties. MediciNova has evaluated ibudilast in clinical studies for conditions including progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance use disorders.